Oxurion completes phase 2 enrollment for anti-PlGF, anti-VEGF combination therapy for DME

Enrollment is complete in a phase 2 trial of the anti-PlGF THR-317 in combination with the anti-VEGF ranibizumab for the treatment of diabetic macular edema, Oxurion announced in a press release.
Seventy patients were enrolled in the study, which will evaluate the safety and efficacy of three monthly intravitreal injections of THR-317 and ranibizumab, the release said. Control patients will receive ranibizumab and sham injections.
“We are delighted to announce the earlier than anticipated full enrollment of our phase 2 study evaluating THR-317 in combination with ranibizumab for the

Full Story →